AstraZeneca to publish full US trial results after criticism of ‘outdated’ data use – Sydney Morning Herald

The data really are quite good but when they put it into the press release it wasnt completely accurate, he said.
In addition to the 79 per cent efficacy in stopping symptomatic illness in the trial conducted in the United States, Chile and Peru, the data reported on Monday also showed the shot was 100 per cent effective against severe or critical forms of the disease and posed no increased risk of blood clots.
On Sunday, Australias Therapeutic Goods Administration approved the locally manufactured…

Click here to view the original article.